Lilly Duloxetine Tradename Candidates Could Include Amverse, Xerflect
This article was originally published in Pharmaceutical Approvals Monthly
Lilly has submitted eight trade names to the Patent and Trademark Office that could be candidates for its serotonin/norepinephrine reuptake inhibitor duloxetine. The company proposed the names Amverse, Conflect, Conprise, Entreve, Rethera, Vyceum, Xercate and Xerflect for agents that act on central nervous system disorders or treat and prevent urinary incontinence.
You may also be interested in...
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
The paradoxical finding that Dendreon's cancer immunotherapeutic Provenge (sipuleucel-T) improved overall survival in men with metastatic castration-resistant prostate cancer but did not appear to slow the progression of the disease is raising questions about the future of clinical development for the burgeoning class